JP2019503706A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503706A5
JP2019503706A5 JP2018547863A JP2018547863A JP2019503706A5 JP 2019503706 A5 JP2019503706 A5 JP 2019503706A5 JP 2018547863 A JP2018547863 A JP 2018547863A JP 2018547863 A JP2018547863 A JP 2018547863A JP 2019503706 A5 JP2019503706 A5 JP 2019503706A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding portion
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547863A
Other languages
English (en)
Japanese (ja)
Other versions
JP6849694B2 (ja
JP2019503706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/064140 external-priority patent/WO2017095875A1/en
Publication of JP2019503706A publication Critical patent/JP2019503706A/ja
Publication of JP2019503706A5 publication Critical patent/JP2019503706A5/ja
Application granted granted Critical
Publication of JP6849694B2 publication Critical patent/JP6849694B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547863A 2015-11-30 2016-11-30 抗ヒトip−10抗体およびそれらの使用 Expired - Fee Related JP6849694B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562261210P 2015-11-30 2015-11-30
US62/261,210 2015-11-30
US201662374622P 2016-08-12 2016-08-12
US62/374,622 2016-08-12
PCT/US2016/064140 WO2017095875A1 (en) 2015-11-30 2016-11-30 Anti human ip-10 antibodies and their uses

Publications (3)

Publication Number Publication Date
JP2019503706A JP2019503706A (ja) 2019-02-14
JP2019503706A5 true JP2019503706A5 (cg-RX-API-DMAC7.html) 2019-10-03
JP6849694B2 JP6849694B2 (ja) 2021-03-24

Family

ID=57570588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547863A Expired - Fee Related JP6849694B2 (ja) 2015-11-30 2016-11-30 抗ヒトip−10抗体およびそれらの使用

Country Status (6)

Country Link
US (2) US10556948B2 (cg-RX-API-DMAC7.html)
EP (1) EP3383903A1 (cg-RX-API-DMAC7.html)
JP (1) JP6849694B2 (cg-RX-API-DMAC7.html)
KR (1) KR102630475B1 (cg-RX-API-DMAC7.html)
CN (1) CN108602885B (cg-RX-API-DMAC7.html)
WO (1) WO2017095875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11698358B2 (en) 2017-09-07 2023-07-11 Bristol-Myers Squibb Company Method of purity determination by capillary electrophoresis
JP2021519752A (ja) * 2018-03-29 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 単量体モノクローナル抗体を精製する方法
CA3116878A1 (en) * 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
JP2022540674A (ja) 2019-07-15 2022-09-16 ブリストル-マイヤーズ スクイブ カンパニー 抗trem-1抗体およびその使用
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021119761A1 (en) * 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
DE60140136D1 (en) 2000-08-18 2009-11-19 Univ California Kheiten
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US20030166589A1 (en) 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis
JP2005501036A (ja) 2001-07-12 2005-01-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 二次的な組織変性のcxcl10処置
US20040096446A1 (en) 2001-08-17 2004-05-20 Lane Thomas E. Methods for treating demyelinating diseases
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
WO2004045525A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2004101511A2 (en) 2003-05-09 2004-11-25 Protein Design Labs, Inc Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
DE602004031772D1 (de) 2003-12-04 2011-04-21 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
EP1708961B1 (en) * 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
PL1691837T3 (pl) 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
WO2008106200A2 (en) 2007-02-28 2008-09-04 Novimmune Sa Human anti-ip-10 antibodies and uses thereof
CA2834552A1 (en) * 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses

Similar Documents

Publication Publication Date Title
JP2019503706A5 (cg-RX-API-DMAC7.html)
US10442857B2 (en) Anti-IL-17 antibodies
TWI848905B (zh) 用於治療補體介導之疾病及病症之方法
JP2014511844A5 (cg-RX-API-DMAC7.html)
JP6962915B2 (ja) 改善されたtnf結合因子
JP2012500020A5 (cg-RX-API-DMAC7.html)
JP2019522961A5 (cg-RX-API-DMAC7.html)
AU2015206002B2 (en) Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
CN106102837A (zh) 经由细胞受体锚定使用具有天然架构的双特异性抗体改良的hiv‑1‑中和抗体效力和广度
FI3468990T3 (fi) Anti-C5-vasta-aineita ja niiden käyttöjä
JP2011516084A5 (cg-RX-API-DMAC7.html)
JP2019503990A5 (cg-RX-API-DMAC7.html)
JP2016508153A5 (cg-RX-API-DMAC7.html)
JP2018502060A5 (cg-RX-API-DMAC7.html)
RU2015143886A (ru) Антитела к тау и способы применения
JP2007514419A5 (cg-RX-API-DMAC7.html)
JP2019521647A5 (cg-RX-API-DMAC7.html)
JP2011514150A5 (cg-RX-API-DMAC7.html)
JP2019525728A5 (cg-RX-API-DMAC7.html)
JP2022517441A (ja) Btla抗体
JP2018529661A5 (cg-RX-API-DMAC7.html)
JP2020512368A5 (cg-RX-API-DMAC7.html)
JPWO2020059847A5 (cg-RX-API-DMAC7.html)
WO2017059813A1 (zh) 抗乙肝表面抗原的抗体及其用途
JP2021504321A5 (cg-RX-API-DMAC7.html)